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Abstract
Background: Initial reports in May 2009 of the novel influenza strain H1N1pdm estimated a case fatality rate (CFR) of 0.6%,
similar to that of seasonal influenza. In July 2009, however, Argentina reported 3056 cases with 137 deaths, representing a
CFR of 4.5%. Potential explanations for increased CFR included virus reassortment or genetic drift, or infection of a more
vulnerable population. Virus genomic sequencing of 26 Argentinian samples representing both severe and mild disease
indicated no evidence of reassortment, mutations associated with resistance to antiviral drugs, or genetic drift that might
contribute to virulence. Furthermore, no evidence was found for increased frequency of risk factors for H1N1pdm disease.
Methods/Principal Findings: We examined nasopharyngeal swab samples (NPS) from 199 cases of H1N1pdm infection from
Argentina with MassTag PCR, testing for 33 additional microbial agents. The study population consisted of 199 H1N1pdm-
infected subjects sampled between 23 June and 4 July 2009. Thirty-nine had severe disease defined as death (n=20) or
hospitalization (n=19); 160 had mild disease. At least one additional agent of potential pathogenic importance was
identified in 152 samples (76%), including Streptococcus pneumoniae (n=62); Haemophilus influenzae (n=104); human
respiratory syncytial virus A (n=11) and B (n=1); human rhinovirus A (n=1) and B (n=4); human coronaviruses 229E (n=1)
and OC43 (n=2); Klebsiella pneumoniae (n=2); Acinetobacter baumannii (n=2); Serratia marcescens (n=1); and
Staphylococcus aureus (n=35) and methicillin-resistant S. aureus (MRSA, n=6). The presence of S. pneumoniae was
strongly correlated with severe disease. S. pneumoniae was present in 56.4% of severe cases versus 25% of mild cases; more
than one-third of H1N1pdm NPS with S. pneumoniae were from subjects with severe disease (22 of 62 S. pneumoniae-
positive NPS, p=0.0004). In subjects 6 to 55 years of age, the adjusted odds ratio (OR) of severe disease in the presence of S.
pneumoniae was 125.5 (95% confidence interval [CI], 16.95, 928.72; p,0.0001).
Conclusions/Significance: The association of S. pneumoniae with morbidity and mortality is established in the current and
previous influenza pandemics. However, this study is the first to demonstrate the prognostic significance of non-invasive
antemortem diagnosis of S. pneumoniae infection and may provide insights into clinical management.
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Introduction
On June 11, 2009, the World Health Organization (WHO)
declared a pandemic outbreak of respiratory illness associated with
the novel influenza A (H1N1) virus (H1N1pdm). Infection with
H1N1pdm was considered mild; however, the strain seemed to be
highly transmissible. Based on a study in the community of La
Gloria, Mexico, where the virus was first detected early in 2009,
and worldwide surveillance data and mathematical modeling, the
CFR was estimated to be 0.6% [1]. The first case in Argentina was
reported on May 17, 2009; by July 16, 2009, just two months later,
the number of cases in Argentina totaled 3056, with 137 deaths,
representing a computed CFR of 4.5% [2].
Although we could not exclude the possibility that this elevated
CFR reflected underreporting of milder infections, the alternative,
a bona fide increase due to differences at the level of host or
pathogen, might have global implications. Risk factors commonly
associated with development of severe disease, including advanced
age, chronic illnesses (diabetes, asthma, obesity) or immunosup-
pression (other immune-mediated diseases, immunomodulatory
therapies, pregnancy), were not present at increased frequency in
Argentina. Another potential explanation for the higher CFR was
a change in the virus, including reassortment with a more virulent
strain, development of resistance to antiviral therapies, or genetic
drift, resulting in a more virulent phenotype. Complete genome
sequencing of 26 samples representing both severe and mild cases
of disease from Argentina did not reveal evidence consistent with
development of a more virulent phenotype (data not shown). A
third factor we considered was bacterial and viral coinfection.
Although disease severity in previous pandemics has been
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H1N1pdm-infected individuals in developed countries failed to
correlate severe disease with coinfection [2,4,5].
To evaluate the contribution of coinfection to the mortality
observed in Argentina, we examined 199 cases of previously-
diagnosed H1N1pdm infections from Argentina, including 39
cases classified as severe and 160 cases categorized as mild, using
MassTag PCR, a multiplex PCR system that assesses 30 to 40
microbial agents in a single reaction [6].
Results
NPS specimens from 199 H1N1pdm-positive patients, collected
between June 23 and July 4 during the course of an outbreak
investigation of pandemic H1N1 influenza in Argentina, were
analyzed by MassTag PCR for the presence of potential sources of
coinfection, including 33 viral and bacterial respiratory pathogens.
Prior to initiating MassTag PCR studies, the presence of
H1N1pdm was confirmed for all samples with the WHO-
approved Real Time PCR H1N1pdm assay [7].
Subjects included 39 patients classified with severe disease,
based on hospitalization (n=19) or death (n=20), and 160
patients with mild disease, who presented to ambulatory clinics.
Five patients had medical conditions associated with increased risk
of severe disease following influenza infection (asthma, malnutri-
tion, pregnancy, obesity, immunosuppression; n=1 each). Four of
these patients (80%) had severe disease; 1 had mild disease
(p=0.0056).
To examine whether the age groups typically associated with
greater risk of influenza-related complications – i.e., young
children and the elderly [8] – were also at higher risk for more
severe disease in the context of H1N1pdm, we compared the
severity of disease in subjects ,6 years of age or .55 years of age
(high risk age group) with that found in subjects 6 to 55 years of
age (low risk age group; age data available for 181 subjects).
Although the mean age of severe and mild disease subjects was
similar, severe disease occurred in 14 of 26 (53.8%) of high risk age
group subjects as compared with 20 of 155 (12.9%) of the low risk
age group subjects (Fisher’s exact test, p,0.0001; Table 1).
However, of the 34 patients with severe disease for whom age data
were available, 20 (58.8%) were from the low risk age group
(Fisher’s exact test, p,0.0001). There was a trend toward a higher
prevalence of severe disease in males (20 of 80, or 25.0%) as
compared with females (15 of 104, or 14.4%; p=0.09).
Data concerning antiviral and antibiotic therapy were available
for 120 subjects. Risk of severe disease was diminished in subjects
who received only oseltamivir. Of 96 subjects receiving oseltama-
vir alone, 10 (10.4%) had severe disease. In contrast, 13 of 14
patients (92.9%) who received antibiotics without antiviral
medication had severe disease (p,0.0001).
MassTag PCR assays
MassTag PCR detected H1N1pdm and at least one additional
potential respiratory pathogen in 152 of 199 samples (76.4%). Co-
infecting agents included S. pneumoniae (n=62); H. influenzae
(n=104); human respiratory syncytial virus (RSV) A (n=11)
and B (n=1); human rhinovirus (HRV) A (n=1) and B (n=4);
human coronavirus (HCoV) 2229 (n=1) and -OC43 (n=2); K.
pneumoniae (n=2); A. baumannii (n=2); S. marcescens (n=1); and S.
aureus (n=35) and MRSA (n=6) (Table 2). In all cases, the only
influenza virus found was H1N1pdm. The presence of S.
pneumoniae was associated with severe disease. S. pneumoniae was
detected in 56.4% of severe cases, but only 25.0% of mild cases;
more than one-third of H1N1pdm NPS with S. pneumoniae were
from subjects with severe disease (22 of 62 S. pneumoniae-positive
NPS, p=0.0004; Table 2). H. influenzae infection was frequent in
Table 1. Characteristics of H1N1pdm influenza subjects.
SUBJECT CHARACTERISTIC DISEASE SEVERITY ALL SUBJECTS
Severe Mild
(total n=39) (total n=160) (total n=199)
n( % ) n( % ) n( % )
AGE Subjects with available age data 34 (87.2) 147 (91.8) 181 (91.0)
in years, mean6SD 27.8621.6* 23.9615.5 24.7616.8
AGE RISK CATEGORY High risk: ,6o r.55 years 14 (41.2)** 12 (8.2) 26 (14.4)
Low risk: 6–55 years 20 (58.8) 135 (91.8) 155 (85.6)
SEX Subjects with available sex data 35 (89.7) 149 (93.1) 184 (92.5)
Female 15 (42.9)
1 89 (59.7) 104 (56.5)
Male 20 (57.1) 60 (40.3) 80 (43.5)
ANTI-MICROBIAL STATUS Subjects with available drug data 29 (74.3) 91 (56.9) 120 (60.3)
No antimicrobial drugs 3 (10.3)
" 2 (2.2) 5 (4.2)
Antiviral drugs only 10 (34.5) 86 (94.5) 96 (80.0)
Antibacterial drugs only 13 (44.8) 1 (1.1) 14 (11.7)
Antivirals + antibacterials 3 (10.3) 2 (2.2) 5 (4.2)
MEDICAL RISK FACTOR 4 (10.3)
# 1 (0.6) 5 (2.5)
*Mann-Whitney U, p=ns.
**p,0.0001.
1p=0.09.
"p,0.0001.
#p=0.0056.
doi:10.1371/journal.pone.0008540.t001
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agent – but was not increased among subjects with severe disease.
Whereas 95 of the 160 mild H1N1pdm cases (59.4%) were positive
for this bacterium, H. influenzae was only detected in 9 of 39 severe
H1N1 cases (23.1%, p,0.0001). Other bacterial agents were
detected in 45 cases, including S. aureus (n=35), MRSA (n=6), K.
pneumoniae (n=2), S. marcescens (n=1), and A. baumannii (n=2). Of
the 45 subjects with one or more bacterial respiratory pathogens
other than S. pneumoniae or H. influenzae in their NPS samples, 44
had mild disease (97.8%; p=0.0004).
The presence of RSV A, though relatively infrequent, was more
common in severe (6 of 39 cases, 15.4%) than in mild disease (5 of
160 cases, 3.1%; p=0.0085). Other viruses, including RSV B,
HRV and HCoV, were also infrequent (9 of 199 cases, 4.5%).
Only 1 such case (HRV B) had severe disease.
The significance of the relationship between S. pneumoniae and
severe disease was restricted to patients in the low risk age group
(p,0.0001; Table 3). To more closely examine the influence of
the presence of S. pneumoniae in NPS samples on H1N1pdm
severity as a function of age-associated risk, we pursued
multivariable logistic regression analysis stratified by age risk
group. A model adjusting for the presence in NPS of RSV A, the
total number of agents detected in NPS, and the presence of a
medical risk factor implicated in severe H1N1 outcomes was
derived after ensuring that relationships among included variables
were low (nonsignificant contingency coefficients ranging from
Table 2. Coinfection patterns in severe and mild H1N1pdm influenza.
AGENT(S) DETECTED DISEASE SEVERITY ALL SUBJECTS
(n=199)
n( % )
Severe Mild
(n=39) (n=160)
n( % ) n( % )
S. pneumoniae 22 (56.4)* 40 (25.0) 62 (35.5)
H. influenzae 9 (23.1)** 95 (59.4) 104 (52.3)
S. aureus (any) 1 (2.6)*** 40 (25.0) 41 (20.6)
Methicillin-resistant S. aureus (MRSA) 0 (0.0) 6 (3.7) 6 (3.0)
Other bacterial respiratory pathogens
{ 0 (0.0) 5 (3.1) 5 (2.5)
(K. pneumoniae, S. marcescens, A. baumannii)
RSV A 6 (15.4)
" 5 (3.1) 11 (5.5)
Other viruses
{{ 1 (2.6) 8 (5.0) 9 (4.5)
(HRV, HCoV-229E, HCoV-OC43, RSV B)
Any coinfection 15 (38.5) 110 (68.7) 125 (62.8)
Other bacterial agent 6 S. pneumoniae OR Any virus in addition to H1N1
Coinfection in addition to S. pneumoniae (n=62) 10 (25.6) 30 (18.7) 40 (20.1)
Other coinfection without S. pneumoniae (n=137) 5 (12.8)
"" 80 (50.0) 85 (42.7)
*p=0.0004; ** p,0.0001; *** p=0.0008;
" p=0.0085;
"" p=0.0017.
{No evidence of other bacterial respiratory pathogens in any subjects, including: C. pneumoniae; L. pneumophila; M. pneumoniae; M. tuberculosis; N. meningitides; C.
albicans; Enterobacter spp; Enterococcus spp.; Pseudomonas spp.; S. pyogenes.
{{No evidence of other viral respiratory pathogens in any subjects, including: strains of FLUAV other than H1N1pdm, FLUBV, HPIV 1-4, HMPV, HEV, HAdV. The A.
baumannii-positive case was also positive for S. aureus.
doi:10.1371/journal.pone.0008540.t002
Table 3. Relationship of S. pneumoniae coinfection to H1N1 influenza disease severity, stratified by age risk category.
AGE RISK CATEGORY PRESENCE OF AGENT DISEASE SEVERITY ALL SUBJECTS
Severe Mild
(n=34)* (n=147)* (n=181)
HIGH RISK S. pneumoniae (+) 7 (50.0) 7 (58.3) 14 (53.8)
Age ,6o r.55 years (n=26) S. pneumoniae (2) 7 (50.0) 5 (41.7) 12 (46.1)
LOW RISK S. pneumoniae (+) 13 (65.0)
1 27 (20.0) 40 (25.8)
Age 6–55 years (n=155) S. pneumoniae (2) 7 (35.0) 108 (80.0) 115 (74.2)
*Restricted to subjects with age data.
1p,0.0001.
doi:10.1371/journal.pone.0008540.t003
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years), the adjusted OR for the contribution of S. pneumoniae-
positivity to severe disease outcomes in this logistic regression
model was 125 (95% CI, 16.95, 928.72; p,0.0001, Table 4. The
presence of a risk-associated medical condition was associated with
increased risk of severe disease (OR [95% CI], 15.31 [1.21,
193.49], p=0.0358); the total number of agents detected was
inversely related to severe disease outcomes (OR [95% CI], 0.11
[0.03, 0.38; p=0.0005). Results of the logistic regression analysis
were not significant for subjects with high age-associated risk (,6
or .55 years of age).
Discussion
Secondary bacterial infections have been implicated in
morbidity and mortality in H1N1 influenza [3]. Analysis of lung
tissue sections from fatal 1918 influenza case materials frequently
revealed histopathologic findings consistent with acute bacterial
pneumonia [3]. Agents recovered by postmortem cultures of lung
samples from 96 fatal 1918 influenza pandemic cases included S.
pneumoniae (23.2%), S. haemolyticus (18.0%), S. aureus (7.7%) and H.
influenzae (4.7%) [3].
In our study of Argentinean victims of H1N1pdm, the presence
of S. pneumoniae in NPS predicts severe disease outcome. The risk
associated with S. pneumoniae is particularly prominent in 6-to-55
year-old individuals. Indeed, severity of disease in this low risk
group can be predicted with 90.97% accuracy via a multivariable
logistic regression model that considers the presence of S.
pneumoniae together with viruses other than influenza and a risk-
associated medical condition.
In the first wave of pediatric H1N1pdm admissions in
Birmingham, UK, only low rates of bacterial infection were found
(10 out of 63 children, 15.8%) [4]. A case series of the first 18
H1N1pdm-infected patients hospitalized in Mexico City reported
no evidence of coinfection with other common respiratory viruses
[5]. In contrast to these initial reports based on clinical data,
wherein coinfection was infrequent, recent postmortem analyses
indicated lower respiratory tract infection in 22 out of 77 lethal
2009 H1N1pdm cases in the United States (29%) [9]; S. pneumoniae
was implicated in 10 of these cases.
Synergistic pathogenesis is described between influenza virus
and S. pneumoniae. Madhi and colleagues demonstrated that
vaccination against S. pneumoniae reduces the frequency of
pneumonia associated with influenza A, RSV and parainfluenza
viruses [10]. In animal models, influenza neuraminidase has been
shown to strip sialic acid residues to expose pneumococcal
receptors on respiratory epithelium [11]. Indeed, the potency of
neuraminidase is correlated with the capacity of an influenza virus
strain to promote pneumonia [12].
Three practical implications emerge from our study. First, S.
pneumoniae is important in the pathogenesis and prognosis of
H1N1pdm-associated disease. Whether this effect is associated
with S. pneumoniae sui generis or only with specific serotypes
remains to be determined. Second, easily accessible samples such
as NPS may be used as an index to risk of severe disease. Third,
multiplex diagnostic methods like MassTag PCR can enable rapid
detection of a broad spectrum of viral and bacterial agents and
inform clinical care.
Materials and Methods
Data Collection
As is the routine during infectious disease outbreaks, specimens
were collected at individual hospitals and point-of-care institutions
in Argentina and submitted to the Administracion Nacional de
Laboratorios e Institutos de Salud (ANLIS). Clinical information
and samples submitted to ANLIS were assigned a new unique
identifier to deidentify both the clinical data and biological
samples; absence of any personally-identifying information was
assured. Samples were submitted under deidentified codes to
Instituto Nacional de Enfermedades Infecciosas (INEI) for
H1N1pdm testing. Samples for this study were randomly selected
at ANLIS by review of deidentified clinical information provided
to ANLIS from hospital and point-of-care institutions on the basis
of their review of charts in their own institutions. INEI and
Columbia University (CU) were provided the following deidenti-
fied data: patient age, sex, presence of prior medical conditions
known to be associated with greater morbidity and mortality after
influenza infection (e.g., diabetes, chronic pulmonary disease,
cardiovascular disease, obesity, immunosuppression, pregnancy),
use of antimicrobial drugs, date of sample acquisition and
geographic region of patient residence. Information about other
potential factors associated with risk of severe H1N1 disease,
including presence of passive tobacco smoke exposure, older
siblings, or personal and/or familial atopic background, was
unavailable. Both INEI and CU maintain approved Institutional
Review Board (IRB) protocols for receipt and analysis of
deidentified samples and their associated deidentified clinical data.
Subjects and Specimens
Samples for this study were 199 H1N1pdm-positive NPS
specimens collected at ANLIS in Buenos Aires, Argentina.
Samples were randomly selected for analysis from two types of
repository specimens maintained by ANLIS and collected during
the course of standard H1N1pdm surveillance procedures from
hospital and clinics in Argentina during the period 06/23/2009 to
07/04/2009: (1) NPS samples from mild H1N1pdm cases
(n=160), and (2) NPS samples from severe H1N1pdm cases
(n=39). Mild H1N1 cases were defined as ambulatory cases of
confirmed H1N1 infection; severe H1N1 disease was defined on
the basis of either death (n=20) or severe pneumonia requiring
hospitalization or mechanical assistance (n=19). Prior to selection
of samples for analysis, deidentified clinical information from
hospital and clinics was used by approved ANLIS personnel to
classify cases as mild or severe. Specimens were submitted to the
INEI and archived at 270uC following testing for H1N1pdm by
the WHO-approved Real Time PCR test [7]. During the same
period (epidemiological weeks 25 and 26), 1496 RSV infections
(15.6% out of 9595 virus-positive cases) were reported by the
Argentinian national respiratory disease surveillance system in
Table 4. Relationship of presence of S. pneumoniae in NPS to H1N1pdm disease severity in 6-to-55 year-old subjects.
Variable Unadjusted odds ratio (95% CI) p value Adjusted odds ratio (95% CI)* p value
S. pneumoniae (+) 7.43 (2.70, 20.42) 0.0001 125.46 (16.95, 928.72) ,0.0001
*Adjusted for presence of RSV A in NPS, total number of agents detected in NPS, and presence of medical risk factor. Likelihood ratio of model fit, p,0.0001.
doi:10.1371/journal.pone.0008540.t004
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typing information), 23 FLUBV (0.2%), 161 HPIV (1.7%) and 48
HAdV (0.5%) cases of severe acute respiratory disease [13].
To determine whether patterns of coinfection with other
respiratory pathogens among H1N1pdm-positive patients with
severe disease differed from coinfection patterns observed in those
with mild disease, 39 NPS specimens were selected randomly from
a total of 1769 severe cases, and studied along with 160 NPS
selected randomly from among 1282 H1N1pdm-infected ambu-
latory (mild) cases. Both groups of samples were collected from 6/
23/2009 to 7/4/2009.
Laboratory Assays
Total RNA from NPS was obtained by acid guanidinium
thiocyanate-phenol-chloroform extraction (TRI-Reagent, Molec-
ular Research Center).
Samples were prepared and analyzed by MassTag PCR [6,14]
for 33 microbes using 3 panels targeting: generic influenza A virus
(FLUAV), influenza B virus (FLUBV), RSV A, RSV B, HCoV
OC43 and 229E, human parainfluenza (HPIV) 1-4, human
metapneumovirus (HMPV), human enteroviruses (HEV), HRV
(A, B and C), human adenovirus (HAdV), C. pneumoniae, H.
influenzae, L. pneumophila, M. pneumoniae, M. tuberculosis, N.
meningitides, S. pneumoniae, A. baumannii, C. albicans, Enterobacter spp.,
Enterococcus spp., K. pneumoniae, S. aureus, methicillin-resistant S.
aureus, Pseudomonas spp., S. marcescens, and S. pyogenes [6].
Statistics
Group comparisons were conducted using nonparametric tests
(Mann-Whitney U test) for continuous data deviating from normal
distributions and Fisher’s Exact Test for nominal data. Two-tailed
tests for significance were pursued in all analyses. To examine
H1N1pdm disease severity as a function of S. pneumoniae
coinfection, we created a multivariable logistic regression model,
stratified by age risk category (high risk, age ,6o r.55 years; low
risk, age 6–55 years). The outcome of interest was disease severity
(severe disease: hospitalized or fatal H1N1pdm cases; mild disease:
non-hospitalized, nonfatal community H1N1pdm cases). The
model was adjusted for RSV A coinfection, the total number of
bacterial or viral agents detected in NPS, and the presence of a
medical risk factor. All variables were checked for correlation with
each other and with the disease severity dependent variable by
deriving contingency coefficients. The goodness-of-fit test was used
to determine the fit of the logistic regression model to the data.
StatView for Windows, version 5.0.1 (SAS Institute) and SPSS for
Windows, version 17.0 (SPSS, Inc.) statistical software were
employed for these analyses. Test levels for significance were
p,0.05.
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